Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498

1.

Megakaryocyte polyploidization: role in platelet production.

Vainchenker W, Raslova H.

Platelets. 2019 Sep 22:1-10. doi: 10.1080/09537104.2019.1667497. [Epub ahead of print]

PMID:
31544577
2.

MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.

Lutzmann M, Bernex F, da Costa de Jesus C, Hodroj D, Marty C, Plo I, Vainchenker W, Tosolini M, Forichon L, Bret C, Queille S, Marchive C, Hoffmann JS, Méchali M.

Cell Rep. 2019 Sep 10;28(11):2851-2865.e4. doi: 10.1016/j.celrep.2019.07.095.

3.

Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, Kralovics R, Van den Eynde BJ, Defour JP, Constantinescu SN.

Leukemia. 2019 Aug 30. doi: 10.1038/s41375-019-0538-1. [Epub ahead of print]

PMID:
31471561
4.

Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging.

Ho YH, Del Toro R, Rivera-Torres J, Rak J, Korn C, García-García A, Macías D, González-Gómez C, Del Monte A, Wittner M, Waller AK, Foster HR, López-Otín C, Johnson RS, Nerlov C, Ghevaert C, Vainchenker W, Louache F, Andrés V, Méndez-Ferrer S.

Cell Stem Cell. 2019 Sep 5;25(3):407-418.e6. doi: 10.1016/j.stem.2019.06.007. Epub 2019 Jul 11.

5.

The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications.

Vainchenker W, Plo I, Marty C, Varghese LN, Constantinescu SN.

Expert Rev Hematol. 2019 Jun;12(6):437-448. doi: 10.1080/17474086.2019.1617129. Epub 2019 May 22.

PMID:
31092065
6.

Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.

Beke A, Laplane L, Riviere J, Yang Q, Torres-Martin M, Dayris T, Rameau P, Saada V, Bilhou-Nabera C, Hurtado A, Lordier L, Vainchenker W, Figueroa ME, Droin N, Solary E.

Haematologica. 2019 May 2. pii: haematol.2018.208488. doi: 10.3324/haematol.2018.208488. [Epub ahead of print]

7.

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, Albu RI, Defour JP, Nivarthi H, Hug E, Xu E, Ould-Amer Y, Mouton C, Colau D, Vertommen D, Shwe MM, Marty C, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2019 Jun 20;133(25):2669-2681. doi: 10.1182/blood-2018-09-874578. Epub 2019 Mar 22.

PMID:
30902807
8.

Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Toppaldoddi KR, da Costa Cacemiro M, Bluteau O, Panneau-Schmaltz B, Pioch A, Muller D, Villeval JL, Raslova H, Constantinescu SN, Plo I, Vainchenker W, Marty C.

Oncogene. 2019 Mar;38(10):1651-1660. doi: 10.1038/s41388-018-0538-z. Epub 2018 Oct 19.

PMID:
30846848
9.

Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity.

Donada A, Balayn N, Sliwa D, Lordier L, Ceglia V, Baschieri F, Goizet C, Favier R, Tosca L, Tachdjian G, Denis CV, Plo I, Vainchenker W, Debili N, Rosa JP, Bryckaert M, Raslova H.

Blood. 2019 Apr 18;133(16):1778-1788. doi: 10.1182/blood-2018-07-861427. Epub 2019 Jan 2.

10.

Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome.

Bellanné-Chantelot C, Schmaltz-Panneau B, Marty C, Fenneteau O, Callebaut I, Clauin S, Docet A, Damaj GL, Leblanc T, Pellier I, Stoven C, Souquere S, Antony-Debré I, Beaupain B, Aladjidi N, Barlogis V, Bauduer F, Bensaid P, Boespflug-Tanguy O, Berger C, Bertrand Y, Carausu L, Fieschi C, Galambrun C, Schmidt A, Journel H, Mazingue F, Nelken B, Quah TC, Oksenhendler E, Ouachée M, Pasquet M, Saada V, Suarez F, Pierron G, Vainchenker W, Plo I, Donadieu J.

Blood. 2018 Sep 20;132(12):1318-1331. doi: 10.1182/blood-2017-12-820308. Epub 2018 Jun 18.

11.

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN.

F1000Res. 2018 Jan 17;7:82. doi: 10.12688/f1000research.13167.1. eCollection 2018. Review.

12.

The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70.

Gastou M, Rio S, Dussiot M, Karboul N, Moniz H, Leblanc T, Sevin M, Gonin P, Larghéro J, Garrido C, Narla A, Mohandas N, Vainchenker W, Hermine O, Solary E, Da Costa L; French Society of Hematology (SFH); French Society of Immunology and Hematology (SHIP).

Blood Adv. 2017 Oct 10;1(22):1959-1976. doi: 10.1182/bloodadvances.2017008078. eCollection 2017 Oct 10.

13.

CK2: a key regulator of thrombopoiesis.

Vainchenker W, Raslova H.

Blood. 2017 Dec 21;130(25):2695-2697. doi: 10.1182/blood-2017-10-808568. No abstract available.

PMID:
29269531
14.

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis.

Pasquier F, Marty C, Balligand T, Verdier F, Grosjean S, Gryshkova V, Raslova H, Constantinescu SN, Casadevall N, Vainchenker W, Bellanné-Chantelot C, Plo I.

Haematologica. 2018 Apr;103(4):575-586. doi: 10.3324/haematol.2017.176370. Epub 2017 Dec 21.

15.

Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.

Messaoudi K, Ali A, Ishaq R, Palazzo A, Sliwa D, Bluteau O, Souquère S, Muller D, Diop KM, Rameau P, Lapierre V, Marolleau JP, Matthias P, Godin I, Pierron G, Thomas SG, Watson SP, Droin N, Vainchenker W, Plo I, Raslova H, Debili N.

Nat Commun. 2017 Nov 27;8(1):1786. doi: 10.1038/s41467-017-01690-2.

16.

Megakaryocyte and polyploidization.

Mazzi S, Lordier L, Debili N, Raslova H, Vainchenker W.

Exp Hematol. 2018 Jan;57:1-13. doi: 10.1016/j.exphem.2017.10.001. Epub 2017 Oct 27. Review.

PMID:
29111429
17.

Identification of MPL R102P Mutation in Hereditary Thrombocytosis.

Bellanné-Chantelot C, Mosca M, Marty C, Favier R, Vainchenker W, Plo I.

Front Endocrinol (Lausanne). 2017 Sep 20;8:235. doi: 10.3389/fendo.2017.00235. eCollection 2017.

18.

Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Plo I, Bellanné-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W.

Front Endocrinol (Lausanne). 2017 Sep 12;8:234. doi: 10.3389/fendo.2017.00234. eCollection 2017. Review.

19.

ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.

Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T.

Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

20.

Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaravel S, Wickrema A, Migliaccio A, Gurbuxani S, Vainchenker W, Platanias LC, Tefferi A, Crispino JD.

J Clin Invest. 2017 Apr 3;127(4):1316-1320. doi: 10.1172/JCI82905. Epub 2017 Feb 27.

21.

Non-apoptotic functions of caspases in myeloid cell differentiation.

Solier S, Fontenay M, Vainchenker W, Droin N, Solary E.

Cell Death Differ. 2017 Aug;24(8):1337-1347. doi: 10.1038/cdd.2017.19. Epub 2017 Feb 17. Review.

22.

P53 deletion and NrasG12D cooperate for AML.

Vainchenker W, Plo I.

Blood. 2017 Jan 19;129(3):271-273. doi: 10.1182/blood-2016-11-750547. No abstract available.

PMID:
28104674
23.

An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.

Favale F, Messaoudi K, Varghese LN, Boukour S, Pecquet C, Gryshkova V, Defour JP, Albu RI, Bluteau O, Ballerini P, Leverger G, Plo I, Debili N, Raslova H, Favier R, Constantinescu SN, Vainchenker W.

Blood. 2016 Dec 29;128(26):3146-3158. doi: 10.1182/blood-2016-06-722058. Epub 2016 Nov 10.

PMID:
28034873
24.

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Vainchenker W, Kralovics R.

Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Review.

PMID:
28028029
25.

Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.

Manchev VT, Bouzid H, Antony-Debré I, Leite B, Meurice G, Droin N, Prebet T, Costello RT, Vainchenker W, Plo I, Diop M, Macintyre E, Asnafi V, Favier R, Baccini V, Raslova H.

J Cell Mol Med. 2017 Jun;21(6):1237-1242. doi: 10.1111/jcmm.13051. Epub 2016 Dec 20.

26.

Eltrombopag, a potent stimulator of megakaryopoiesis.

Raslova H, Vainchenker W, Plo I.

Haematologica. 2016 Dec;101(12):1443-1445. No abstract available.

27.

CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress.

Zhang Y, Dépond M, He L, Foudi A, Kwarteng EO, Lauret E, Plo I, Desterke C, Dessen P, Fujii N, Opolon P, Herault O, Solary E, Vainchenker W, Joulin V, Louache F, Wittner M.

Sci Rep. 2016 Nov 25;6:37827. doi: 10.1038/srep37827.

28.

Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes.

Roy A, Lordier L, Mazzi S, Chang Y, Lapierre V, Larghero J, Debili N, Raslova H, Vainchenker W.

Blood. 2016 Dec 29;128(26):3137-3145. doi: 10.1182/blood-2016-04-711630. Epub 2016 Oct 13.

PMID:
27737892
29.

The cell division control protein 42-Src family kinase-neural Wiskott-Aldrich syndrome protein pathway regulates human proplatelet formation.

Palazzo A, Bluteau O, Messaoudi K, Marangoni F, Chang Y, Souquere S, Pierron G, Lapierre V, Zheng Y, Vainchenker W, Raslova H, Debili N.

J Thromb Haemost. 2016 Dec;14(12):2524-2535. doi: 10.1111/jth.13519. Epub 2016 Nov 15.

30.

Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint.

Roy A, Lordier L, Pioche-Durieu C, Souquere S, Roy L, Rameau P, Lapierre V, Le Cam E, Plo I, Debili N, Raslova H, Vainchenker W.

Haematologica. 2016 Dec;101(12):1469-1478. Epub 2016 Aug 11.

31.

Aspects biologiques de la voie JAK/STAT dans les néoplasmes myéloprolifératifs classiques négatifs pour BCR-ABL.

Mosca M, Vertenoeil G, Toppaldoddi KR, Plo I, Vainchenker W.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S16-28. doi: 10.1016/S0007-4551(16)30142-4. Review. French.

PMID:
27494969
32.

CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.

Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, Barosi G, Louache F.

Oncotarget. 2016 Jul 22;8(33):54082-54095. doi: 10.18632/oncotarget.10789. eCollection 2017 Aug 15.

33.

EZH2: a molecular switch of the MPN phenotype.

Vainchenker W, Plo I.

Blood. 2016 Jun 30;127(26):3297-8. doi: 10.1182/blood-2016-04-711770. No abstract available.

PMID:
27365409
34.

ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies.

Plo I, Bellanné-Chantelot C, Vainchenker W.

Mol Cell Oncol. 2015 Oct 29;3(2):e1094564. doi: 10.1080/23723556.2015.1094564. eCollection 2016 Mar.

35.

TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.

Mahfoudhi E, Talhaoui I, Cabagnols X, Della Valle V, Secardin L, Rameau P, Bernard OA, Ishchenko AA, Abbes S, Vainchenker W, Saparbaev M, Plo I.

DNA Repair (Amst). 2016 Jul;43:78-88. doi: 10.1016/j.dnarep.2016.05.031. Epub 2016 May 24.

PMID:
27289557
36.

Recent advances in understanding myelofibrosis and essential thrombocythemia.

Vainchenker W, Constantinescu SN, Plo I.

F1000Res. 2016 Apr 19;5. pii: F1000 Faculty Rev-700. doi: 10.12688/f1000research.8081.1. eCollection 2016. Review.

37.

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.

Balligand T, Achouri Y, Pecquet C, Chachoua I, Nivarthi H, Marty C, Vainchenker W, Plo I, Kralovics R, Constantinescu SN.

Leukemia. 2016 Aug;30(8):1775-8. doi: 10.1038/leu.2016.47. Epub 2016 Feb 29. No abstract available.

PMID:
26987905
38.

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.

Mahfoudhi E, Lordier L, Marty C, Pan J, Roy A, Roy L, Rameau P, Abbes S, Debili N, Raslova H, Chang Y, Debussche L, Vainchenker W, Plo I.

Oncotarget. 2016 May 31;7(22):31980-92. doi: 10.18632/oncotarget.7881.

39.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E.

Nat Commun. 2016 Feb 24;7:10767. doi: 10.1038/ncomms10767.

40.

Thrombopoietin receptor is required for the oncogenic function of CALR mutants.

Nivarthi H, Chen D, Cleary C, Kubesova B, Jäger R, Bogner E, Marty C, Pecquet C, Vainchenker W, Constantinescu SN, Kralovics R.

Leukemia. 2016 Aug;30(8):1759-63. doi: 10.1038/leu.2016.32. Epub 2016 Feb 17. No abstract available.

41.

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.

PMID:
26668133
42.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W.

Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.

PMID:
26608331
43.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin N, Chachoua I, Favier R, Diop MK, Ugo V, Casadevall N, Debili N, Raslova H, Bellanné-Chantelot C, Constantinescu SN, Bluteau O, Plo I, Vainchenker W.

Blood. 2016 Jan 21;127(3):333-42. doi: 10.1182/blood-2015-07-661983. Epub 2015 Oct 8.

PMID:
26450985
44.

Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.

Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, Pasquier F, Valle VD, Secardin L, Leroy G, Mahfoudhi E, Grosjean S, Droin N, Diop M, Dessen P, Charrier S, Palazzo A, Merlevede J, Meniane JC, Delaunay-Darivon C, Fuseau P, Isnard F, Casadevall N, Solary E, Debili N, Bernard OA, Raslova H, Najman A, Vainchenker W, Bellanné-Chantelot C, Plo I.

Nat Genet. 2015 Oct;47(10):1131-40. doi: 10.1038/ng.3380. Epub 2015 Aug 17.

PMID:
26280900
45.

Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology.

Laplane L, Beke A, Vainchenker W, Solary E.

Stem Cells. 2015 Oct;33(10):2887-92. doi: 10.1002/stem.2099. Epub 2015 Jul 29. Review.

46.

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.

Debeurme F, Lacout C, Moratal C, Bagley RG, Vainchenker W, Adrian F, Villeval JL.

J Cell Mol Med. 2015 Nov;19(11):2564-74. doi: 10.1111/jcmm.12608. Epub 2015 Jul 14.

47.

[Properties and biological roles of TET proteins during embryogenesis and in hematopoiesis].

Mahfoudhi E, Secardin L, Scourzic L, Bernard O, Vainchenker W, Plo I.

Med Sci (Paris). 2015 Mar;31(3):268-74. doi: 10.1051/medsci/20153103012. Epub 2015 Apr 8. Review. French.

48.

Distinct localizations and roles of non-muscle myosin II during proplatelet formation and platelet release.

Badirou I, Pan J, Souquere S, Legrand C, Pierron G, Wang A, Eckly A, Roy A, Gachet C, Vainchenker W, Chang Y, Léon C.

J Thromb Haemost. 2015 May;13(5):851-9. doi: 10.1111/jth.12887. Epub 2015 Apr 1.

49.

A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.

Cabagnols X, Cayuela JM, Vainchenker W.

N Engl J Med. 2015 Feb 12;372(7):688-90. doi: 10.1056/NEJMc1413718. No abstract available.

PMID:
25671272
50.

TET2 loss, a rescue of JAK2V617F HSCs.

Vainchenker W, Plo I.

Blood. 2015 Jan 8;125(2):212-3. doi: 10.1182/blood-2014-10-606624.

PMID:
25573967

Supplemental Content

Loading ...
Support Center